This study compares eloralintide and tirzepatide, given alone or together, with placebo in adults who have obesity or overweight and type 2 diabetes. Participants were managed with diet and exercise alone or a stable dose of metformin, with or without an SGLT2 inhibitor, and had an HbA1c between 7.0% and 10.5%. Participation lasted about 64 weeks. The study ran under Lilly’s chronic weight management master protocol (NCT06143956), in the United States and Argentina.
On 30 September 2026 Lilly announced topline results. It reported mean weight change at 48 weeks of -23.3% for the highest eloralintide plus tirzepatide combination, against -14.8% for tirzepatide 15 mg alone and -3.0% for placebo, and -8.2% to -12.3% for eloralintide alone across its three dose levels. HbA1c fell by 2.9 percentage points for the highest combination, 2.4 for tirzepatide alone and 0.3 for placebo. Lilly said the most common adverse events were gastrointestinal, generally mild or moderate, mostly during dose escalation, and seen more often in the combination groups than with either drug alone. Discontinuation due to adverse events was 10.8% to 27.0% with the combination, 0% to 10.8% with eloralintide alone, 2.9% with tirzepatide and 16.7% with placebo. Lilly said it plans to start Phase 3 by the fourth quarter of 2026.
Read with care: these are a sponsor’s topline numbers from a press release, not a peer-reviewed paper, and no confidence intervals or p-values were given. Everyone in the study has type 2 diabetes, so the weight figures should not be set beside the Phase II study in adults without diabetes (NCT06230523). The registry lists exclusions for a resting pulse below 60 or above 100 bpm, a history of sinus bradycardia and recent symptomatic gallbladder disease, so participants were selected. A registry record describes a study’s plan and status. It is not a result, and it does not show that the drug works or is safe.
Study context
What the study tests
This Phase 2 study compares eloralintide (listed as LY3841136) and tirzepatide, alone or together, with placebo, double-blind, in adults with obesity or overweight and type 2 diabetes. It runs under the chronic weight management master protocol (NCT06143956). The primary endpoint is percent change in body weight from baseline to week 48. The record lists 367 participants and about 64 weeks of participation.
Who can take part
Adults aged 18 to 75 need type 2 diabetes with an HbA1c from 7.0% to 10.5%, treated for at least three months with diet and exercise alone or with a stable dose of metformin, with or without an SGLT2 inhibitor. They also need a BMI of at least 27 and a stable body weight. Exclusions include an eGFR below 45, a history of pancreatitis and a history of bradyarrhythmia or sinus bradycardia. Sites are in the United States and Argentina.
What the registry does not say
The study is marked completed, with primary completion on 1 July 2026, but no results are posted. HbA1c, the share of participants losing 5% or 10% of body weight and drug levels are secondary measures, so they are registered plans, not findings.
Source: ClinicalTrials.gov record NCT06603571, read on 2026-10-15. Registered plans can change.